- Home
- RANI vs FGNX Comparison
RANI vs FGNX Comparison
Compare RANI & FGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- FGNX
- Stock Information
- Founded
- RANI 2012
- FGNX 1932
- Country
- RANI United States
- FGNX United States
- Employees
- RANI N/A
- FGNX N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- FGNX Property-Casualty Insurers
- Sector
- RANI Health Care
- FGNX Finance
- Exchange
- RANI Nasdaq
- FGNX Nasdaq
- Market Cap
- RANI 23.2M
- FGNX 25.2M
- IPO Year
- RANI 2021
- FGNX N/A
- Fundamental
- Price
- RANI $0.50
- FGNX $9.63
- Analyst Decision
- RANI Strong Buy
- FGNX
- Analyst Count
- RANI 4
- FGNX 0
- Target Price
- RANI $7.75
- FGNX N/A
- AVG Volume (30 Days)
- RANI 677.7K
- FGNX 173.7K
- Earning Date
- RANI 08-07-2025
- FGNX 08-07-2025
- Dividend Yield
- RANI N/A
- FGNX N/A
- EPS Growth
- RANI N/A
- FGNX N/A
- EPS
- RANI N/A
- FGNX 2.41
- Revenue
- RANI $1,200,000.00
- FGNX $24,184,000.00
- Revenue This Year
- RANI N/A
- FGNX N/A
- Revenue Next Year
- RANI N/A
- FGNX N/A
- P/E Ratio
- RANI N/A
- FGNX $4.29
- Revenue Growth
- RANI N/A
- FGNX 24.03
- 52 Week Low
- RANI $0.39
- FGNX $9.08
- 52 Week High
- RANI $3.75
- FGNX $41.25
- Technical
- Relative Strength Index (RSI)
- RANI 45.69
- FGNX N/A
- Support Level
- RANI $0.44
- FGNX N/A
- Resistance Level
- RANI $0.58
- FGNX N/A
- Average True Range (ATR)
- RANI 0.04
- FGNX 0.00
- MACD
- RANI -0.01
- FGNX 0.00
- Stochastic Oscillator
- RANI 32.74
- FGNX 0.00
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.